Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1 week. Subjects with the SLCO1B1 c.521CC genotype (n=4) had a 144% (P<0.001) or 61% (P=0.049) greater mean area under the plasma atorvastatin concentration-time curve from 0 to 48 h (AUC(0-48 h)) than those with the c.521TT (n=16) or c.521TC (n=12) genotype, respectively. The AUC(0-48 h) of 2-hydroxyatorvastatin was 100% greater in subjects with the c.521CC genotype than in those with the c.521TT genotype (P=0.018). Rosuvastatin AUC(0-48 h) and peak plasma concentration (Cmax) were 65% (P=0.002) and 79% (P=0.003) higher in subjects with the c.521CC genotype than in those with the c.521TT genotype. These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationPharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationA Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationNiemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Self-citationRosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
The National Heart, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401520 · Cited by 537
The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.053 · Cited by 502
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., Maxwell, W. D., McLeod, H. L., Krauss, R. M., Roden, D. M., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.125 · Cited by 433
Self-citationShitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., & Sugiyama, Y. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1823 · Cited by 418
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Drug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C.-H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4156 · Cited by 349
Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332
Self-citationTransporter Pharmacogenetics and Statin Toxicity
Niemi, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 330
Self-citationStatin-induced myopathy: a review and update
Abd, T. T., & Jacobson, T. A. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540568 · Cited by 322
Role of OATP Transporters in the Disposition of Drugs
Niemi, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.787 · Cited by 266
Self-citationNies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., Schwab, M., & Schaeffeler, E. (2013) · Genome Medicine · doi:10.1186/gm405 · Cited by 265
Self-citationRare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Ramsey, L. B., Bruun, G. H., Yang, W., Treviño, L. R., Vattathil, S., Scheet, P., Cheng, C., Rosner, G. L., Giacomini, K. M., Fan, Y., et al. (2012) · Genome Research · doi:10.1101/gr.129668.111 · Cited by 261
Human skeletal muscle drug transporters determine local exposure and toxicity of statins
Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., & Tirona, R. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.203596 · Cited by 222
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_3 · Cited by 222
Maeda, K., Ikeda, Y., Fujita, T., Yoshida, K., Azuma, Y., Haruyama, Y., Yamane, N., Kumagai, Y., & Sugiyama, Y. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.142 · Cited by 211
Chu, X., Liao, M., Shen, H., Yoshida, K., Zur, A. A., Arya, V., Galetin, A., Giacomini, K. M., Hanna, I., Kusuhara, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1216 · Cited by 205
Brunham, L. R., Lansberg, P. J., Zhang, L., Miao, F., Carter, C., Hovingh, G. K., Visscher, H., Jukema, J. W., Stalenhoef, A. F., Ross, C. J. D., et al. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.92 · Cited by 199
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 196
“Reasons for ongoing uncertainty regarding the role of rs4149056 in ATV myotoxicity include fewer ATV cases in studies (especially cases on high dose ATV) [89] and ATV appears less intrinsically myotoxic than SVT [165], as well as the impact of rs4149056 on exposure being smaller for ATV than SVT acid [172].”
BackgroundDeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., et al. (2013) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000099 · Cited by 195
Prasad, B., Evers, R., Gupta, A., Hop, C. E. C. A., Salphati, L., Shukla, S., Ambudkar, S. V., & Unadkat, J. D. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053819 · Cited by 195
Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.85 · Cited by 189
Self-citationGlobal Analysis of Genetic Variation in SLCO1B1
Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.19 · Cited by 183
“521T>C SNP (and the *15 haplotype) is a low-activity variant as it has been associated with a markedly reduced uptake activity of OATP1B1 substrates in vitro and increased plasma concentrations in vivo in a number of studies [5,9,12,14–21,24,26,41].”
BackgroundSelf-citationThe influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
Romaine, S. P. R., Bailey, K. M., Hall, A. S., & Balmforth, A. J. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.54 · Cited by 170
Jamei, M., Bajot, F., Neuhoff, S., Barter, Z., Yang, J., Rostami-Hodjegan, A., & Rowland-Yeo, K. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0097-y · Cited by 163
“78 Range [20, 47]”
Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers
Kiser, J. J., Gerber, J. G., Predhomme, J. A., Wolfe, P., Flynn, D. M., & Hoody, D. W. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318160a542 · Cited by 160
“3 mM), 55–57 and genetic polymorphisms in the SLCO1B1 gene (which encodes OATP1B1) have been shown to alter rosuvastatin PK significantly.(58,59) Rosuvastatin is also a substrate for BCRP (km = 10.”
BackgroundBirmingham, B. K., Bujac, S. R., Elsby, R., Azumaya, C. T., Wei, C., Chen, Y., Mosqueda-Garcia, R., & Ambrose, H. J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1801-z · Cited by 153
Impact of genetic variation in OATP transporters to drug disposition and response
Gong, I. Y., & Kim, R. B. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-099 · Cited by 137
Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy
Stringer, H. A. J., Sohi, G. K., Maguire, J. A., & Côté, H. C. F. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.023 · Cited by 79
Efflux and uptake transporters as determinants of statin response
Rodrigues, A. C. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003713519 · Cited by 64
“521C allele causes reduced OATP1B1 activity, thus increasing plasma concentration of statins [66-70].”
BackgroundOATP1B1/1B3 activity in plated primary human hepatocytes over time in culture
Ulvestad, M., Björquist, P., Molden, E., Åsberg, A., & Andersson, T. B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.076 · Cited by 40
“The 521T>C (174Val > Ala) polymorphism, which is present in the SLCO1B1*5, *15 and *17 haplotypes, has been associated with reduced clearance of OATP1B1 substrates [12,23,43–45].”
BackgroundWojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2111 · Cited by 38
Metadata
- Authors
- Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-02
- Volume
- 82
- Issue
- 6
- Pages
- 726-733
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2152218609
- Cited by
- 432
- References
- 54
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.